ATAI

Company Overview — What Does ATAI Life Sciences N.V. Do?

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany. ATAI Life Sciences N.V. (ATAI) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Florian Brand and employs approximately 80 people. With a market capitalization of $1.3B, ATAI is one of the notable companies in the Healthcare sector.

ATAI Life Sciences N.V. (ATAI) Stock Rating — Reduce (April 2026)

As of April 2026, ATAI Life Sciences N.V. receives a Reduce rating with a composite score of 34.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ATAI ranks #2,319 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ATAI Life Sciences N.V. ranks #276 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATAI Stock Price and 52-Week Range

ATAI Life Sciences N.V. (ATAI) currently trades at $3.72. The stock gained $0.02 (0.5%) in the most recent trading session. The 52-week high for ATAI is $6.75, which means the stock is currently trading -44.9% from its annual peak. The 52-week low is $1.15, putting the stock 223.5% above its annual trough. Recent trading volume was 2.3M shares, reflecting moderate market activity.

Is ATAI Overvalued or Undervalued? — Valuation Analysis

ATAI Life Sciences N.V. (ATAI) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.61x, versus the sector average of 2.75x. The price-to-sales ratio is 449.42x, compared to 1.66x for the average Healthcare stock.

At current multiples, ATAI Life Sciences N.V. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ATAI Life Sciences N.V. Profitability — ROE, Margins, and Quality Score

ATAI Life Sciences N.V. (ATAI) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -88.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.1% versus the sector average of -33.1%.

On a margin basis, ATAI Life Sciences N.V. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -16281.6% (sector: -66.1%). Net profit margin stands at -19873.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 174.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATAI Debt, Balance Sheet, and Financial Health

ATAI Life Sciences N.V. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.90x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $30M.

ATAI has a beta of 1.31, meaning it is more volatile than the broader market — a $10,000 investment in ATAI would be expected to move 30.6% more than the S&P 500 on any given day. The stability factor score for ATAI Life Sciences N.V. is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ATAI Life Sciences N.V. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ATAI Life Sciences N.V. reported revenue of $3M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-142M. Gross margin was 100.0%. Operating income came in at $-97M.

In Q3 2025, ATAI Life Sciences N.V. reported revenue of $749,000 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-61M. Revenue grew 1772.5% year-over-year compared to Q3 2024. Operating income came in at $-28M.

In Q2 2025, ATAI Life Sciences N.V. reported revenue of $719,000 and earnings per share (EPS) of $-0.14. Net income for the quarter was $-28M. Revenue grew 163.4% year-over-year compared to Q2 2024. Operating income came in at $-25M.

In Q1 2025, ATAI Life Sciences N.V. reported revenue of $2M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-26M. Operating income came in at $-20M.

Over the past 8 quarters, ATAI Life Sciences N.V. has demonstrated a growth trajectory, with revenue expanding from $0 to $3M. Investors analyzing ATAI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATAI Dividend Yield and Income Analysis

ATAI Life Sciences N.V. (ATAI) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATAI Momentum and Technical Analysis Profile

ATAI Life Sciences N.V. (ATAI) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

ATAI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ATAI Life Sciences N.V. (ATAI) ranks #276 out of 838 stocks based on the Blank Capital composite score. This places ATAI in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATAI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATAI vs S&P 500 (SPY) comparison to assess how ATAI Life Sciences N.V. stacks up against the broader market across all factor dimensions.

ATAI Next Earnings Date

No upcoming earnings date has been announced for ATAI Life Sciences N.V. (ATAI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATAI? — Investment Thesis Summary

The quantitative profile for ATAI Life Sciences N.V. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. High volatility (stability score 26/100) increases portfolio risk.

In summary, ATAI Life Sciences N.V. (ATAI) earns a Reduce rating with a composite score of 34.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATAI stock.

Related Resources for ATAI Investors

Explore more research and tools: ATAI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATAI head-to-head with peers: ATAI vs AZN, ATAI vs SLGL, ATAI vs VMD.